Engineered immune cells take on tough cancers in first human trial
Disease control
Recruiting now
This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Phase 1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC